Patients hospitalized with COVID-19 who have preexisting kidney conditions are more susceptible to renal complications, a new systematic review and meta-analysis suggest.
In 3 trials of sodium zirconium cyclosilicate, serum bicarbonate increased regardless of CKD stage.
According to a new analysis of the AMBER study, more heart failure patients treated with patiromer than placebo remained on spironolactone therapy at 12 weeks.
The risk of hyperkalemia recurrence in patients with chronic kidney disease increases for each hyperkalemia episode a person experiences.
Patients with heart failure who remained on mineralocorticoid receptor antagonists after a hyperkalemia episode had a lower risk for major cardiovascular events than those who stopped taking the medications, a study found.
In 2 small case series of solid-organ transplant recipients, the potassium binders patiromer and sodium zirconium cyclosilicate appeared effective in the short term in managing hyperkalemia.
Personalized nutritional counseling appears essential in maintaining a low-protein diet.
No dominant treatment strategy was observed among 11 nephrology practices across the United States.
In a propensity score-matched analysis, children who discontinued renin-angiotensin-aldosterone system inhibition (RAASi) had significantly faster eGFR decline compared with those who continued RAASi.
In its first label update since sodium zirconium cyclosilicate was approved in 2018, FDA has a dosage regimen specifically to treat hyperkalemia in stable hemodialysis patients.